Most Recent
An Australian fashion designer has asked the High Court to overturn a Full Court win for singer Katy Perry in a long-running trade mark dispute, saying the court's findings “wrongly privilege the powerful and famous over ordinary traders”.
The Full Court has overturned a finding that singer Katy Perry infringed an Australian fashion designer's 'Katie Perry' mark, finding the designer knew of the pop star when she registered the mark.
Appealing her loss in a trade mark stoush with an Australian fashion designer, pop star Katy Perry has argued the woman “should have changed direction” with her ‘Katie Perry’ brand once the singer's star began to rise.
Pop star Katy Perry has appealed her loss in a long-running trade mark fight with an Australian fashion designer over the right to use her name to sell clothing in Australia.
US singer Katy Perry and an Australian fashion designer are at loggerheads over court orders to be made following a judge's finding the pop star was liable for trade mark infringement, with concerns raised that Perry's 'Teenage Dream' shorts could "fall between the cracks".
An infringement ruling against US singer Katy Perry in a case brought by an Australian fashion designer is a "win for the little guy", experts say, showing that fame doesn't give celebrities a blank cheque to exploit their brand at the expense of someone's else's registered trade mark.
In what a judge has dubbed a “tale of two women, two teenage dreams and one name”, US pop star Katy Perry has lost her bid to cancel the “Katie Perry” trade mark owned by an Australian designer and has been barred her from using her stage name to market clothing merchandise.
Israeli drug company Neurim Pharmaceuticals has lost a bid to patent a mini version of its melatonin tablet Circadin for children, after a successful challenge by Australian drug maker Generic Partners.
An Australian fashion designer suing Katy Perry over the rights to use the Katy Perry trade mark in Australia is a "calculating and dishonest witness" whose "utterly dishonest" testimony should not be believed, counsel for the pop star said during closing submissions.
Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its "inherently implausible" opposition to the patent.